Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

• Published in: Nephrology, dialysis, transplantation Vol. 30; no. 10; pp. 1665 - 1673
• Main Authors: Besarab, Anatole, Provenzano, Robert, Hertel, Joachim, Zabaneh, Raja, Klaus, Stephen J., Lee, Tyson, Leong, Robert, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.10.2015
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anemia - drug therapy; Anemia - etiology; Cohort Studies; Dose-Response Relationship, Drug; Erythropoiesis - drug effects; Erythropoietin - metabolism; Female; Glycine - analogs & derivatives; Glycine - therapeutic use; Hemoglobins - metabolism; Hepcidins - metabolism; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors; Isoquinolines - therapeutic use; Male; Middle Aged; Original; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic - complications; Single-Blind Method; Young Adult; chronic kidney disease; hepcidin; HIF-PHI; anemia; erythropoietin

Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects. NDD-CKD subjects with hemoglobin...